This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Vaxart’s 8K filing here.
About Vaxart
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Featured Stories
- Five stocks we like better than Vaxart
- Russell 2000 Index, How Investors Use it For Profitable Trading
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- What is the MACD Indicator and How to Use it in Your Trading
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
- Short Selling: How to Short a Stock
- Gold’s Momentum Persists: Leading ETF and 2 Stocks to Watch
